A Tri-Stimuli Responsive (Maghemite/PLGA)/Chitosan Nanostructure with Promising Applications in Lung Cancer

A (core/shell)/shell nanostructure (production performance ≈ 50%, mean diameter ≈ 330 nm) was built using maghemite, PLGA, and chitosan. An extensive characterization proved the complete inclusion of the maghemite nuclei into the PLGA matrix (by nanoprecipitation solvent evaporation) and the disposition of the chitosan shell onto the nanocomposite (by coacervation). Short-term stability and the adequate magnetism of the nanocomposites were demonstrated by size and electrokinetic determinations, and by defining the first magnetization curve and the responsiveness of the colloid to a permanent magnet, respectively. Safety of the nanoparticles was postulated when considering the results from blood compatibility studies, and toxicity assays against human colonic CCD-18 fibroblasts and colon carcinoma T-84 cells. Cisplatin incorporation to the PLGA matrix generated appropriate loading values (≈15%), and a dual pH- and heat (hyperthermia)-responsive drug release behaviour (≈4.7-fold faster release at pH 5.0 and 45 °C compared to pH 7.4 and 37 °C). The half maximal inhibitory concentration of the cisplatin-loaded nanoparticles against human lung adenocarcinoma A-549 cells was ≈1.6-fold less than that of the free chemotherapeutic. Such a biocompatible and tri-stimuli responsive (maghemite/PLGA)/chitosan nanostructure may found a promising use for the effective treatment of lung cancer.

Physicochemical compatibility studies of triclosan and flurbiprofen with excipients of pharmaceutical formulation using binary, ternary, and multi-combination approach

Background The aim of the study was to evaluate the suitability of triclosan (TCS) and flurbiprofen (FLB) with poly-ε-caprolactone (PCL), chitosan (CS), and Kolliphor® P188 (KP) for possible application in the design of nano-formulations. Results Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and scanning electron microscopy (SEM) revealed the physical characteristics of the various sample compositions without any apparent interaction. The Fourier transform infrared spectroscopy (FTIR)’s spectra of the physical mixtures showed their characteristic absorption bands with broadening and overlapping of bands in some instances, but no appearance of new bands was observed. Conclusion The study revealed the physical form stability of the evaluated components after the storage period and lack of definite pharmaceutical incompatibility between them. Thus, the selected drugs and excipients could be used for the development of pharmaceutical nano-formulations.

Microbial inoculants and Trichoderma viride consortia for growth promotion and disease management in ginger

A study was conducted to evaluate the effect of microbial inoculants consortia on ginger under field conditions. Three biofertilizers comprising of Azospirillum lipoferum (nitrogen fixer KAU-AZO), Bacillus megaterium (phosphate solubilizer KAU-PSB), Bacillus sporothermodurans (potash solubilizer KAU-KSB) and two biocontrol agents namely, Pseudomonas fluorescen (KAU-PF) and Trichoderma viride (KAU-TV) were used in the study. Compatibility studies revealed that all the isolates were compatible with each other. However, P. fluorescens and T. viride were incompatible with each other under in vitro. Under field evaluation, consortia of microbial inoculants performed better than the single inoculants in terms of yield and disease management. The organic Adhoc package recorded the minimum incidence of rhizome rot (2.09 %) among all the treatments. However, KAU-AZO + KAU-PSB + KAU-KSB + KAU-TV recorded the minimum rhizome rot (5.23%) incidence among the consortia. In the case of Rhizoctonia leaf blight disease, consortia of KAU-AZO + KAU-PSB + KAU-KSB + KAU-PF showed the minimum incidence (5.21%). In general, consortium of A. lipoferum, B. megaterium (PSB), B. sporothermodurans (KSB) and T. viride was the most efficient for plant growth promotion and disease management in ginger.

Formulation and Invitro evaluation of immediate release tablets containing febuxostat

In the present research work, Febuxostat Immediate Release Tablet was prepared by direct compression method using varying concentrations of Lycoat, Crospovidone& Croscarmellose sodium as disintegrants. The formulations prepared were evaluated for precompression& post-compression parameters. From the drug excipient compatibility studies, we observe that there are no interactions between the pure drug (Febuxostat) and optimized formulation (Febuxostat+ excipients) which indicates there are no physical changes. Post compression parameters were found to be within the limits. Among the formulation prepared the tablet containing 12mg of CCS shows 98.13% of the drug release within 45 min & follows first-order kinetics.